Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cardiotoxicity × dapagliflozin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Polycystic Ovary Syndrome 4 Prostatic Neoplasms 2 Solid Tumors 1 Pediatric Brain Tumor 1 Pancreatic Neoplasms 1 Obesity 1 Inflammation 1 Hyperinsulinism 1 Hyperglycemia 1 Hereditary Sensory and Autonomic Neuropathies 1 Heart Failure 1 Diabetes Mellitus, Type 2 1 Diabetes Mellitus 1 Cardiotoxicity 1

Interventions

Doxorubicin 15 Echocardiography 13 Exercise 7 Dexrazoxane 7 Cyclophosphamide 7 Trastuzumab 6 Electrocardiography 6 Razoxane 5 Carvedilol 5 Vincristine 4 Filgrastim 4 Radiotherapy 3 Methotrexate 3 Granulocyte Colony-Stimulating Factor 3 Etoposide 3 Docetaxel 3 Cisplatin 3 Atorvastatin 3 salicylhydroxamic acid 2 sacubitril and valsartan sodium hydrate drug combination 2 empagliflozin 2 Tablets 2 Social Determinants of Health 2 Prednisone 2 Magnetic Resonance Spectroscopy 2 Leucovorin 2 Ivabradine 2 High-Intensity Interval Training 2 Chemotherapy, Adjuvant 2 Blood Specimen Collection 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06341842 2024-04-02

PROTECT

Fondazione IRCCS Policlinico San Matteo di Pavia

Phase 2 Recruiting

Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡